Synergistic Anti-tumorigenic Effects of Cabazitaxel and Usnic Acid Combination on Metastatic Castration-Resistant Prostate Cancer Cells


Cite item

Full Text

Abstract

Background:Prostate cancer (PC) affects millions of men, causing high mortality rates. Despite the treatment approaches, the options for metastatic castration-resistant prostate cancer (mCRPC), a lethal form of advanced PC, are still limited. Cabazitaxel (Cbx) is the last taxane-derived chemotherapeutic approved for Docetaxel- resistant mCRPC patients. However, its effects are limited due to the activation of several pathways. Therefore, new approaches are needed to increase the efficacy of Cbx. Usnic acid (UA) is a natural product with wellknown anti-tumorigenic and synergistic effects with various chemotherapeutics. Although the cytotoxicity of UA and Cbx has been evaluated on mCRPC cells, the anti-tumorigenic effect of UA combination with any taxane has not been investigated yet. Thus, we aimed to evaluate the possible synergistic effect of Cbx+UA in mCRPC cells.

Methods:Cell viability and apoptosis were analyzed using WST-1 and Annexin-V. Morphological changes were visualized by fluorescent staining. Finally, cell cycle, mitochondrial health, and ROS levels were determined.

Results:Based on WST-1 results, 25 μM UA exhibited significant additive and synergistic effects with the use of Cbx. Annexin V and cell cycle results showed that UA significantly enhanced the Cbx efficacy at increasing doses compared to using only Cbx (**p<0.01). Moreover, combined treatment significantly increased ROS levels and mitochondrial membrane depolarization compared with Cbx alone (**p<0.01).

Conclusions:Thus, the results suggest that UA increased the anti-tumorigenic effects of Cbx on mCRPC cells by increasing apoptosis, causing an increase in intracellular ROS and disrupting mitochondrial health. Consequently, combining UA and Cbx offers a new combined therapeutic strategy for mCRPC treatment.

About the authors

Ceyda Bergel

Department of Medical Biology, Faculty of Medicine, Bursa Uludag University

Email: info@benthamscience.net

Isil Ezgi Eryilmaz

Department of Medical Biology, Faculty of Medicine, Bursa Uludag University

Author for correspondence.
Email: info@benthamscience.net

Ebrucan Bulut

Department of Medical Biology, Faculty of Medicine, Bursa Uludag University

Email: info@benthamscience.net

Rumeysa Balaban

Department of Medical Biology, Faculty of Medicine, Bursa Uludag University

Email: info@benthamscience.net

Unal Egeli

Department of Medical Biology, Faculty of Medicine, Bursa Uludag University

Email: info@benthamscience.net

Gulsah Cecener

Department of Medical Biology, Faculty of Medicine, Bursa Uludag University

Email: info@benthamscience.net

References

  1. Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin., 2023, 73(1), 17-48. doi: 10.3322/caac.21763 PMID: 36633525
  2. Nouri-Majd, S.; Salari-Moghaddam, A.; Aminianfar, A.; Larijani, B.; Esmaillzadeh, A. Association between red and processed meat consumption and risk of prostate cancer: A systematic review and meta-analysis. Front. Nutr., 2022, 9, 801722. doi: 10.3389/fnut.2022.801722 PMID: 35198587
  3. Leung, D.K.W.; Chiu, P.K.F.; Ng, C.F.; Teoh, J.Y.C. Novel strategies for treating castration-resistant prostate cancer. Biomedicines, 2021, 9(4), 339. doi: 10.3390/biomedicines9040339 PMID: 33801751
  4. Saad, F.; Hotte, S.J. Guidelines for the management of castrate-resistant prostate cancer. Can. Urol. Assoc. J., 2010, 4(6), 380-384. doi: 10.5489/cuaj.10167 PMID: 21191494
  5. Ruiz de Porras, V.; Font, A.; Aytes, A. Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. Cancer Lett., 2021, 523, 162-169. doi: 10.1016/j.canlet.2021.08.033 PMID: 34517086
  6. Tsao, C.K.; Cutting, E.; Martin, J.; Oh, W.K. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther. Adv. Urol., 2014, 6(3), 97-104. doi: 10.1177/1756287214528557 PMID: 24883107
  7. Pobel, C.; Auclin, E.; Procureur, A.; Clément-Zhao, A.; Simonaggio, A.; Delanoy, N.; Vano, Y.A.; Thibault, C.; Oudard, S. Cabazitaxel schedules in metastatic castration-resistant prostate cancer: A review. Future Oncol., 2021, 17(1), 91-102. doi: 10.2217/fon-2020-0672 PMID: 33463373
  8. Bumbaca, B.; Li, W. Taxane resistance in castration-resistant prostate cancer: Mechanisms and therapeutic strategies. Acta Pharm. Sin. B, 2018, 8(4), 518-529. doi: 10.1016/j.apsb.2018.04.007 PMID: 30109177
  9. Duran, G.E.; Wang, Y.C.; Francisco, E.B.; Rose, J.C.; Martinez, F.J.; Coller, J.; Brassard, D.; Vrignaud, P.; Sikic, B.I. Mechanisms of resistance to cabazitaxel. Mol. Cancer Ther., 2015, 14(1), 193-201. doi: 10.1158/1535-7163.MCT-14-0155 PMID: 25416788
  10. Colakoglu, C.; Haciefendi, A.; Eryilmaz, I.E.; Eskiler, G.G.; Egeli, U.; Cecener, G. The cytotoxic effect of usnic acid in malignant melanoma cells with different genomic profiles in the BRAF aspect. WCRJ, 2022, 9, e2240.
  11. Eryilmaz, I.E.; Guney Eskiler, G.; Egeli, U.; Yurdacan, B.; Cecener, G.; Tunca, B. In vitro cytotoxic and antiproliferative effects of usnic acid on hormone‐dependent breast and prostate cancer cells. J. Biochem. Mol. Toxicol., 2018, 32(10), e22208. doi: 10.1002/jbt.22208 PMID: 30101414
  12. Yurdacan, B.; Egeli, U.; Eskiler, G.G.; Eryilmaz, I.E.; Cecener, G.; Tunca, B. The role of usnic acid-induced apoptosis and autophagy in hepatocellular carcinoma. Hum. Exp. Toxicol., 2019, 38(2), 201-215. doi: 10.1177/0960327118792052 PMID: 30084279
  13. Guney Eskiler, G.; Eryilmaz, I.E.; Yurdacan, B.; Egeli, U.; Cecener, G.; Tunca, B. Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor‐positive breast and prostate cancer cells. J. Biochem. Mol. Toxicol., 2019, 33(8), e22338. doi: 10.1002/jbt.22338 PMID: 30980508
  14. Yurdacan, B.; Egeli, U.; Guney Eskiler, G.; Eryilmaz, I.E.; Cecener, G.; Tunca, B. Investigation of new treatment option for hepatocellular carcinoma: A combination of sorafenib with usnic acid. J. Pharm. Pharmacol., 2019, 71(7), 1119-1132. doi: 10.1111/jphp.13097 PMID: 31025377
  15. Wu, W.; Gou, H.; Dong, J.; Yang, X.; Zhao, Y.; Peng, H.; Chen, D.; Geng, R.; Chen, L.; Liu, J. Usnic acid inhibits proliferation and migration through ATM mediated DNA damage response in RKO colorectal cancer cell. Curr. Pharm. Biotechnol., 2021, 22(8), 1129-1138. doi: 10.2174/1389201021666201002155955 PMID: 33006536
  16. Xu, Z.; Xu, L.; Ge, Y.; Sun, H.; Zhu, J.; Dou, Q.; Jia, R. Cabazitaxel suppresses the proliferation and promotes the apoptosis and radiosensitivity of castration-resistant prostate cancer cells by inhibiting PI3K/AKT pathway. Am. J. Transl. Res., 2022, 14(1), 166-181. PMID: 35173836
  17. Değerli, E.; Torun, V.; Cansaran-Duman, D. miR-185-5p response to usnic acid suppresses proliferation and regulating apoptosis in breast cancer cell by targeting Bcl2. Biol. Res., 2020, 53(1), 19. doi: 10.1186/s40659-020-00285-4 PMID: 32366289
  18. Eryilmaz, I.E.; Egeli, U.; Cecener, G. An in vitro redox adaptation model for metastatic prostate cancer: Establishing, characterizing and Cabazitaxel response evaluating. Clin. Exp. Pharmacol. Physiol., 2022, 49(10), 1094-1104. doi: 10.1111/1440-1681.13694 PMID: 35751096
  19. Machioka, K.; Izumi, K.; Kadono, Y.; Iwamoto, H.; Naito, R.; Makino, T.; Kadomoto, S.; Natsagdorj, A.; Keller, E.T.; Zhang, J.; Mizokami, A. Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget, 2018, 9(22), 16185-16196. doi: 10.18632/oncotarget.24609 PMID: 29662635
  20. Oprea-Lager, D.E.; Bijnsdorp, I.V.; VAN Moorselaar, R.J.; VAN DEN Eertwegh, A.J.; Hoekstra, O.S.; Geldof, A.A. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro. Anticancer Res., 2013, 33(2), 387-391. PMID: 23393328
  21. Chou, T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res., 2010, 70(2), 440-446. doi: 10.1158/0008-5472.CAN-09-1947 PMID: 20068163
  22. Kellokumpu-Lehtinen, P.L.; Marttila, T.; Jekunen, A.; Hervonen, P.; Klintrup, K.; Kataja, V.; Utriainen, T.; Luukkaa, M.; Leskinen, M.; Pulkkanen, K.; Kautio, A.L.; Huttunen, T. Biweekly cabazitaxel is a safe treatment option for Metastatic Castration-resistant Prostate Cancer (mCRPC) patients after docetaxel – a final analysis of the prosty II trial. Anticancer Res., 2020, 40(12), 6915-6921. doi: 10.21873/anticanres.14715 PMID: 33288585
  23. Qi, W.; Lu, C.; Huang, H.; Zhang, W.; Song, S.; Liu, B. (+)-usnic acid induces ROS-dependent apoptosis via inhibition of mitochondria respiratory chain complexes and Nrf2 expression in lung squamous cell carcinoma. Int. J. Mol. Sci., 2020, 21(3), 876. doi: 10.3390/ijms21030876 PMID: 32013250
  24. Zhang, S.; Wang, Y.; Chen, Z.; Kim, S.; Iqbal, S.; Chi, A.; Ritenour, C.; Wang, Y.A.; Kucuk, O.; Wu, D. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells. Prostate, 2013, 73(15), 1681-1689. doi: 10.1002/pros.22705 PMID: 23999913
  25. Souchek, J.J.; Davis, A.L.; Hill, T.K.; Holmes, M.B.; Qi, B.; Singh, P.K.; Kridel, S.J.; Mohs, A.M. Combination treatment with orlistat-containing nanoparticles and taxanes is synergistic and enhances microtubule stability in taxane-resistant prostate cancer cells. Mol. Cancer Ther., 2017, 16(9), 1819-1830. doi: 10.1158/1535-7163.MCT-17-0013 PMID: 28615298
  26. Geng, X.; Zhang, X.; Zhou, B.; Zhang, C.; Tu, J.; Chen, X.; Wang, J.; Gao, H.; Qin, G.; Pan, W. Usnic acid induces cycle arrest, apoptosis, and autophagy in gastric cancer cells in vitro and in vivo. Med. Sci. Monit., 2018, 24, 556-566. doi: 10.12659/MSM.908568 PMID: 29374767
  27. Singh, N.; Nambiar, D.; Kale, R.K.; Singh, R.P. Usnic acid inhibits growth and induces cell cycle arrest and apoptosis in human lung carcinoma A549 cells. Nutr. Cancer, 2013, 65(Suppl. 1), 36-43. doi: 10.1080/01635581.2013.785007 PMID: 23682781
  28. Galanty, A.; Koczurkiewicz, P.; Wnuk, D.; Paw, M.; Karnas, E.; Podolak, I.; Węgrzyn, M.; Borusiewicz, M.; Madeja, Z.; Czyż, J.; Michalik, M. Usnic acid and atranorin exert selective cytostatic and anti-invasive effects on human prostate and melanoma cancer cells. Toxicol. In Vitro, 2017, 40, 161-169. doi: 10.1016/j.tiv.2017.01.008 PMID: 28095330
  29. Huo, R.; Wang, L.; Liu, P.; Zhao, Y.; Zhang, C.; Bai, B.; Liu, X.; Shi, C.; Wei, S.; Zhang, H. Cabazitaxel-induced autophagy via the PI3K/Akt/mTOR pathway contributes to A549 cell death. Mol. Med. Rep., 2016, 14(4), 3013-3020. doi: 10.3892/mmr.2016.5648 PMID: 27572899
  30. Kosaka, T.; Hongo, H.; Miyazaki, Y.; Nishimoto, K.; Miyajima, A.; Oya, M. Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer. Oncotarget, 2017, 8(50), 87675-87683. doi: 10.18632/oncotarget.21147 PMID: 29152111
  31. Lima, A.R.; Araújo, A.M.; Pinto, J.; Jerónimo, C.; Henrique, R.; Bastos, M.L.; Carvalho, M.; Guedes de Pinho, P. Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS. Sci. Rep., 2018, 8(1), 5539. doi: 10.1038/s41598-018-23847-9 PMID: 29615722
  32. Chen, S.; Zhang, Z.; Qing, T.; Ren, Z.; Yu, D.; Couch, L.; Ning, B.; Mei, N.; Shi, L.; Tolleson, W.H.; Guo, L. Activation of the Nrf2 signaling pathway in usnic acid-induced toxicity in HepG2 cells. Arch. Toxicol., 2017, 91(3), 1293-1307. doi: 10.1007/s00204-016-1775-y PMID: 27369375

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bentham Science Publishers